Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit
Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of schedule in neuroendocrine tumors.
You may also be interested in...
The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.